ZEO ScientifiX (OTCQB: ZEOX) to host Southeast regenerative medicine webinar for physicians

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

ZEO ScientifiX, Inc. filed an 8-K to highlight a new educational initiative for healthcare professionals. The company will host a live virtual webinar titled “One Year Later, Three States Stronger: The Southeast Regen Revolution” on July 22, 2026, at 6:45 p.m. Eastern Time.

The program will review Florida’s first year under its pioneering stem cell law and discuss similar laws recently adopted in Tennessee and Georgia. Led by General Manager Sean Vega-Stanton, M.D., the expert panel will cover scientific, medical, and regulatory perspectives in regenerative medicine.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Webinar date: July 22, 2026 Webinar time: 6:45 p.m. Eastern Time Number of featured speakers: 3 speakers +1 more

4 metrics

Webinar date July 22, 2026 Scheduled date for live virtual educational webinar

Webinar time 6:45 p.m. Eastern Time Scheduled start time for the webinar

Number of featured speakers 3 speakers Panelists plus hosting General Manager for the webinar

Number of states discussed 3 states Florida, Tennessee, and Georgia stem cell laws

Key Terms

regenerative medicine, stem cell law, clinical-stage biopharmaceutical company, forward-looking statements, +1 more

5 terms

regenerative medicine medical

"advancing regenerative medicine and physician education"

A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.

stem cell law regulatory

"Florida’s first year into their pioneering stem cell law"

clinical-stage biopharmaceutical company financial

"an SEC-reporting, clinical-stage biopharmaceutical company focused on the research"

A clinical-stage biopharmaceutical company develops drugs or medical therapies that are being tested in people in formal clinical trials but do not yet have any approved, marketed products. For investors, these firms behave like prototype makers: their value depends heavily on trial results and regulatory decisions, so they can swing widely on a single study, consume cash while testing, and offer either large upside if trials succeed or big downside if they fail.

forward-looking statements regulatory

"Certain statements contained in this press release should be considered forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

regenerative biologics medical

"focused on the research, development, and manufacturing of regenerative biologics"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/01/2026 - 07:30 AM Accepted by SEC EDGAR 07/01/2026 - 07:30 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 1, 2026

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

Nevada		000-55008		47-4180540
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3321 College Avenue, Suite 246 Davie, Florida		33314
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

Item 8.01 Other Events.

On July 1, 2026, ZEO issued a press release announcing that that it will host a live virtual educational webinar for healthcare professionals titled “One Year Later, Three States Stronger: The Southeast Regen Revolution,” on July 22, 2026, at 6:45 p.m. Eastern Time.

A copy of the press release is included as Exhibit 99.1 to this Report.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.		Description
99.1		Press Release, dated July 1, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 1, 2026	ZEO SCIENTIFIX, INC.

	By:	/s/ Ian T. Bothwell
		Ian T. Bothwell Chief Executive Officer and Chief Financial Officer

Exhibit 99.1

ZEO ScientifiX to Host Live Educational Webinar for Healthcare Professionals Exploring the Southeast Regenerative Medicine Revolution

“One Year Later, Three States Stronger” program will examine lessons learned from Florida’s first year into their pioneering stem cell law and provide physicians from other states an insight of what to prepare for as their state stem cell therapy laws are enacted.

DAVIE, FLORIDA — July 1, 2026 — ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO ScientifiX” or the “Company”), a biologics research and products company dedicated to advancing regenerative medicine and physician education, today announced that it will host a live virtual educational webinar for healthcare professionals, titled “One Year Later, Three States Stronger: The Southeast Regen Revolution,” on July 22, 2026, at 6:45 p.m. Eastern Time.

The webinar will explore what Florida’s first year has taught physicians, discuss the recent adoptions of similar stem cell laws in Tennessee and Georgia, and explore what these developments mean for healthcare providers as regenerative medicine continues to expand across the Southeast.

Designed to provide educational insights and practical perspectives, the program will explore lessons learned from Florida’s first year of implementation and examine the implications for physicians and healthcare providers as additional states continue to expand access to regenerative medicine.

Hosted by ZEO ScientifiX General Manager Sean Vega-Stanton, M.D., the webinar will feature a panel of experts offering scientific, medical, and regulatory perspectives on the rapidly evolving field. Featured speakers include Michael Bellio, Ph.D., Vice President of Research and Manufacturing; George Shapiro, M.D., Chief Medical Officer; and Edgar J. Asebey, Esq., Regulatory Counsel. Together, the panel will provide attendees with insights into the lessons learned during Florida’s first year and what physicians in other states need to know as access to regenerative medicine continues to expand.

As regenerative medicine continues to gain momentum across multiple specialties, ZEO ScientifiX remains committed to advancing physician education and supporting evidence-based discussions surrounding responsible innovation and clinical integration.

Healthcare professionals interested in attending may register here.

About ZEO ScientifiX (OTCQB: ZEOX)

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating out of Nova Southeastern University’s Center of Collaborative Research, the Company translates emerging science into scalable clinical solutions. ZEO ScientifiX supplies clinicians seeking to drive clinical excellence and sustainable practice growth through its cutting-edge biologics and regenerative therapies. For more information, visit https://zeoscientifix.com.

Forward-Looking Statements

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.

Media Contact

ZEO ScientifiX, Inc.
Karlista Maroney
Director of Growth Strategy
ir@zeoscientifix.com

Source: View Original Filing on SEC EDGAR

FAQ

What did ZEO ScientifiX (ZEOX) announce in its latest 8-K filing?

ZEO ScientifiX announced a live virtual educational webinar for healthcare professionals. The event will focus on regenerative medicine and stem cell laws in Florida, Tennessee, and Georgia, offering scientific, medical, and regulatory perspectives from the company’s leadership and expert panelists.

When is the ZEO ScientifiX (ZEOX) regenerative medicine webinar scheduled?

The webinar is scheduled for July 22, 2026, at 6:45 p.m. Eastern Time. It will be a live virtual event for healthcare professionals, focusing on lessons from Florida’s stem cell law and similar developments in Tennessee and Georgia.

What topics will ZEO ScientifiX’s July 22, 2026 webinar cover?

The webinar will explore Florida’s first year under its stem cell law and similar legislation in Tennessee and Georgia. It will examine lessons for physicians, regulatory implications, and expanding access to regenerative medicine across the Southeast from scientific, medical, and legal viewpoints.

Who will speak at the ZEO ScientifiX (ZEOX) Southeast Regen Revolution webinar?

The webinar will be hosted by General Manager Sean Vega-Stanton, M.D. Featured speakers include Michael Bellio, Ph.D., Vice President of Research and Manufacturing; George Shapiro, M.D., Chief Medical Officer; and Edgar J. Asebey, Esq., Regulatory Counsel, covering multiple regenerative medicine perspectives.

What does ZEO ScientifiX (OTCQB: ZEOX) focus on as a business?

ZEO ScientifiX is a clinical-stage biopharmaceutical company focused on regenerative biologics. Operating from Nova Southeastern University’s Center of Collaborative Research, it develops and manufactures biologic products and supplies clinicians with regenerative therapies aimed at clinical excellence and sustainable practice growth.

How does ZEO ScientifiX describe the purpose of its upcoming webinar?

The company describes the webinar as an educational program designed to provide insights and practical perspectives. It aims to share lessons from Florida’s stem cell law implementation and help physicians prepare as more states expand access to regenerative medicine across the Southeast.

Filing Exhibits & Attachments

4 documents

Press Releases

EX-99.1 EXHIBIT 99.1 7.1 KB